Concomitant boost plus large-field preoperative chemoradiation in locally advanced uterine cervix carcinoma: Phase II clinical trial final results (LARA-CC-1)
Highlights
► The surgical safety and pathological efficacy of preoperative 45 Gy concomitant boost CT/RT delivered by a 3D technique is confirmed. ► The delivered doses do not seem sufficient to increase pCR rate in LACC patients. ► IMRT Phase I–II study is actually ongoing to investigate the feasibility of further dose escalation.
Introduction
Exclusive concomitant chemoradiotherapy (CT/RT) represents the standard treatment for locally advanced cervical cancer (LACC) patients on the basis of results from 5 randomized phase III studies that demonstrated an advantage in terms of disease-free survival (DFS) and overall survival (OS) for CT/RT compared to exclusive radiotherapy [1], [2], [3], [4], [5], [6].
In the investigational setting several authors have explored different approaches including neoadjuvant chemotherapy or CT/RT followed by radical surgery with the aim of removing potentially chemo- and radio resistant tumor remnants hence improving local control and possibly overall survival [2], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20]. Clinical outcome results are quite encouraging [2], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20]. Despite the potentially higher risk of side effects and impairment of patients’ quality of life (QoL) related to the use of a trimodal treatment [2], [8], [10], [13], [14], long-term evaluation of toxicity did not show an increased rate and/or severity of complications compared to exclusive CT/RT [14], [21]. Moreover, very recent data from a prospective, longitudinal study assessing QoL and emotional distress in LACC patients with preoperative CT/RT reported an improvement of global health status and anxiety scores over time compared to baseline values although it does not in itself support the use of a trimodal therapy rather than definitive CT/RT [22].
Based on the close relationship between pathological response to treatment and outcome, in the last decade our main objectives in LACC patients were to improve the rate of pathologically assessed response hence modifying the dose and fractionation of cisplatin-based chemoradiation, the treatment time duration or the irradiated volumes [17], [18], [19], [20]. To improve local control by reducing the rate of regional failures in para-aortic nodes as well as in-field recurrences [23], [24], [11], a phase I study (LARA-CC-1 study) was set up by our group to investigate a regimen based on Gross Tumor Volume (GTV) accelerated fractionation and lymph node extended (up to L3 vertebra) field irradiation followed by radical surgery [20]. Results from LARA-CC-1 study established a total dose of 45 Gy given in fractions of 2.25 Gy to macroscopic tumor and a total dose of 40 Gy given in fractions of 2 Gy to lymph node stations as the recommended doses for future studies [20].
Here, we report the final results of LARA-CC-1 Phase II trial aimed at assessing the efficacy of this regimen in terms of pathologically assessed rate of complete response to treatment.
This prospective Phase II study (Large field Radiotherapy in Advanced Cervical Carcinoma, LARA-CC-1) was approved by the Catholic University Institutional Review Board. All patients gave written informed consent agreeing to be submitted to all the procedures described and for their data to be used prospectively. The primary end point of the study was to assess pathologic response, whereas secondary end points included the evaluation of toxicity, surgical morbidity, disease-free survival (DFS) and overall survival (OS).
Patients with histological confirmed, locally advanced (International Federation of Gynaecology and Obstetrics stages IB2–IVA) cervical cancer were eligible for the study. Inclusion criteria were the following: biopsy-proven carcinoma of the cervix, no evidence of disease outside the pelvis, age < 80 years, Eastern Cooperative Oncology Group performance status ≤ 2, adequate bone-marrow function (WBC > 3000/mm3, platelets > 120,000/mm3), adequate renal function (blood urea nitrogen < 25 mg/dL, creatinine < 1.5 mg/dL), normal liver function (bilirubin < 2 mg/dL), and no prior cancer other than basal cell carcinoma. Pre-treatment work up included medical history, clinical examination, chest radiography, abdominal pelvic magnetic resonance imaging (MRI), complete blood cell count, Squamous Cervical Cancer (SCC) and Ca 125 markers, liver and renal function, cystoscopy and proctoscopy were performed if there was any clinical suspicion of invasion.
Simulation and treatment of the patient were performed in a prone position using the UDT (up-down table) device to reduce the small bowel volume in the treatment field [25]. A full bladder during simulation and irradiation was required to minimize the small bowel volume in the boost field. A Computed Tomography (CT) scan with oral contrast was used for planning. The Clinical Target Volume 2 (CTV2) included: primary tumor and positive nodes. Gross Tumor Volume or (GTV) was the upper half or the whole vagina (if clinically involved), uterus, obturatory nodes, external iliac nodes, internal iliac nodes, pre-sacral nodes (cranially to S2–S3 vertebrae), common iliac lymphatic area (pelvic level III) up to its apex and anterior L3 vertebra [26]. The Clinical Target Volume 1 (CTV1) was the GTV plus 1 cm margin. Planning target volumes (PTV2 and PTV1) were defined as the clinical target volume (CTV2 and CTV1) with 8 mm. External beam radiation was delivered on both PTVs using a 3D box technique. The dose to PTV2 was 40 Gy in 2.0 Gy per fraction, a total of 20 fractions for 4 weeks. A concomitant boost total dose of 5 Gy with accelerated fractionation at 0.25 Gy/fraction was delivered to the PTV1 concurrently with PTV2. All the patients were treated with 10–15 MV photons by using an Elekta Precise linear accelerator (Elekta Oncology Systems, Crawley, UK). Treatment was discontinued in patients with grade ≥ 3 toxicity however only resumed if grade 2 toxicity was attained.
Cisplatin (20 mg/m2, 2-hour intravenous infusion for days 1–4) and 5-fluorouracil (1000 mg/m2, 24-hour continuous intravenous infusion for days 1–4) were administered in the first and last weeks of radiotherapy. In case of relapse or progression, patients were considered for salvage treatment.
Four weeks after the end of concomitant CT/RT patients were evaluated for objective response based on post-treatment MRI, SCC and Ca 125 markers and clinical examination. Five to six weeks after the end of CT/RT clinical responders underwent radical hysterectomy according to Piver et al. [27] with bilateral systematic pelvic lymphadenectomy. If pelvic nodes were intraoperatively defined as positive for tumor metastasis, para-aortic lymphadenectomy up to inferior mesenteric artery was carried out. Surgical morbidity was registered and classified [28].
Toxicity assessment was performed according to the Radiation Therapy Oncology Group toxicity criteria and Chassagne grading system [29], [28]. Patients were assessed weekly for acute toxicity during treatment. Operative complications were defined as bladder, ureteral, bowel, vascular injuries, and estimated blood loss exceeding 500 mL. Early and long-term complications were defined as any adverse event occurring within or after 30 days from surgery, respectively. Complications were considered severe (grade 3) if life threatening with permanent organ damage. After surgery, patients underwent physical examination, complete blood count, and blood chemistry every 3 months for the first 2 years and every 6 months thereafter. Chest radiography and abdominal pelvic MRI were performed every 6 months for the first 3 years and yearly thereafter.
Objective tumor response was assessed according to the response evaluation criteria in solid tumors [30]. Pathologic response was defined according to the TNM classification. However, complete response (CR) included cases with absence of any residual tumor after treatment at any site level, while microscopic partial response included cases with persistence of only microscopic foci (≤ 3 mm) at any site level [31].
The sample size was calculated based on the two-stage design by Simon [32]. The design tested the null hypothesis that the true response rate for this population would improve from 45% to the clinically relevant alternative of 65%, using an α error of 0.05 and a β error of 0.2. The sample size was quantified based on previous evidence [10] which showed a rate of pathologically assessed complete response to CT/RT of ∼ 45%. Thus, the first step was planned to include 15 patients; if > 7 patients experienced pathological complete response to treatment, the study would enroll additional 28 patients up to a total number of 43 patients. The regimen would be considered active if > 24 responses were recorded. Considering a 10% drop out rate, a total number of 47 patients were planned.
Disease-free survival (DFS) was calculated from the date of surgery to the date of relapse according to the last follow-up whereas overall survival (OS) was calculated from the date of diagnosis to the date of death or the date of the last follow-up. Medians and life tables were computed using the product limit estimate by the Kaplan–Meier method [33]. Statistical analysis was carried out using SYSTAT, version 11.0 (SPSS, Chicago, IL).
Section snippets
Results
This study included 47 consecutive LACC patients accrued between June 2007 and January 2011 at the Gynaecologic Oncology Unit, Department of Oncology, Catholic University of Campobasso, Italy.
Clinicopathological characteristics and surgical details of patients are summarized in Table 1. Median age was 54 years, range (29–79 years); two-thirds (68%) of patients were FIGO stage IIB, and 57.5% had radiographically positive lymph nodes at staging work up. The majority of tumors were squamous (N = 35,
Discussion
As previously summarized [20], the rationale of the study was based on: 1) intensification of the total dose at sites of macroscopic disease through the use of the concomitant boost technique, 2) reduction of treatment time, with an increase in the effectiveness 3) irradiation of lymph node areas normally excluded from the standard pelvic treatment yet potential sites of micrometastases. We documented a rate of pathologically assessed complete response of 38.6%, a figure which is in line with
Conflict of interest statement
No actual or potential conflicts of interest exist.
Acknowledgment
The authors thank Ms. M. Buwenge for editing and reviewing the manuscript.
References (45)
- et al.
Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery ±/− intraoperative electron beam radiotherapy in locally advanced cervical cancer
Gynecol Oncol
(1999) - et al.
Preoperative concomitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures
Gynecol Oncol
(2007) - et al.
Surgery after concurrent chemoradiotherapy and brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer)
Gynecol Oncol
(2006) - et al.
Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery
Gynecol Oncol
(2010) - et al.
Chemoradiotherapy in locally advanced cancers of the uterine neck. Retrospective study of 92 patients treated at the Institute Curie between 1986 and 1998
Cancer Radiother
(2002) - et al.
Phase I–II trial of preoperative chemoradiation in locally advanced cervical carcinoma
Gynecol Oncol
(2000) - et al.
Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1)
Gynecol Oncol
(2010) - et al.
Role of comorbidities in locally advanced cervical cancer patients administered preoperative chemoradiation: impact on outcome and treatment-related complications
Eur J Surg Oncol
(2012) - et al.
Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study
Gynecol Oncol
(2012) - et al.
Patterns of regional recurrence after definitive radiotherapy for cervical cancer
Int J Radiat Oncol Biol Phys
(2010)
Dislocation of small bowel volume within box pelvic treatment fields, using new “up down table” device
Int J Radiat Oncol Biol Phys
Anatomical bases for the radiological delineation of lymph node areas. Part III: pelvis and lower limbs
Radiother Oncol
A glossary for reporting complications of treatment in gynecological cancers
Radiother Oncol
Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)
Int J Radiat Oncol Biol Phys
Optimal two stage design for phase II clinical trials
Control Clin Trials
Survival and prognostic factors after completion surgery in patients undergoing initial chemoradiation therapy for locally advanced cervical cancer
Gynecol Obstet Fertil
Postoperative morbidity after completion surgery following homogeneous chemoradiation therapy in locally advanced cervical cancer]
J Gynecol Obstet Biol Reprod (Paris)
Dose–effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy
Radiother Oncol
Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer
Radiother Oncol
Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group
Gynecol Oncol
Long-term outcome and prognostic factors for adenocarcinoma/adenosquamouscarcinoma of cervix after definitive radiotherapy
Int J Radiat Oncol Biol Phys
Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma
Gynecol Oncol
Cited by (14)
Could lymphadenectomy be avoided in locally advanced cervical cancer patients administered preoperative chemoradiation? A large-scale retrospective study
2017, European Journal of Surgical OncologyCitation Excerpt :Pretreatment work up had included clinical examination, abdomino-pelvic MRI, complete blood count and measurement of liver and renal function, cystoscopy and proctoscopy if needed. Neo-adjuvant chemoradiation had been administered as whole pelvic irradiation in combination with cisplatin based regimens [20–22]. Response to treatment was evaluated according to the RECIST criteria [23].
Laparoscopic radical hysterectomy after concomitant chemoradiation in locally advanced cervical cancer: A prospective phase II study
2015, Journal of Minimally Invasive GynecologyChemoradiation with concomitant boosts followed by radical surgery in locally advanced cervical cancer: Long-term results of the ROMA-2 prospective phase 2 study
2014, International Journal of Radiation Oncology Biology PhysicsCitation Excerpt :Chest radiography and abdominopelvic MRI were performed every 6 months for the first 3 years and every 12 months thereafter. Sample size was quantified based on previous studies reporting a rate of pathologically assessed complete response to treatment around 40% on average (5-7, 16,23-25). Using the mini-max 2-stage design by Simon (26), we tested the null hypothesis that the true rate of pathologically assessed complete response to treatment would improve from 40.0% to the clinically relevant alternative of 55.0% by using an α error of 0.05 and a β error of 0.1.
Minilaparoscopic nerve sparing radical hysterectomy in locally advanced cervical cancer after neoadjuvant radiochemotherapy
2014, Gynecologic OncologyCitation Excerpt :We report the technique to perform minilaparoscopic nerve sparing radical hysterectomy (NSRH) in locally advanced cervical cancer. Three patients aged 32, 53, and 51 respectively (median 46), with a median body mass index of 23 (18–26), one nulliparous and two pluriparous, were diagnosed with cervical squamous carcinoma on cervical biopsy, FIGO stage II B, and underwent a minilaparoscopic NSRH, bilateral salpingo-oophorectomy and systematic pelvic lymphadenectomy after neoadjuvant radiochemotherapy (pelvic irradiation in 22 fractions 1.8 Gy/day, totaling 39.6 Gy in combination with cisplatin 20 mg/m 2, 2-h intravenous infusion and 5-fluorouracil 1000 mg/m 2, 24-h continuous intravenous infusion, both on days 1–4 and 27–30) according to a protocol in our Institution [1,2]. The procedures required a 5 mm 0° endoscope (Endoeye, Olympus Winter& Ibe GmbH, Hamburg—Germany) inserted in a trans-umbilical optical viewing port (Endopath Xcel, Ethicon Endo-surgery, Cincinnati, OH) and three additional sovrapubic 3-mm diameter ports placed.
Human papillomavirus independent status on pathologic response and outcomes in locally advanced cervical cancer managed with chemoradiotherapy followed by surgery
2023, International Journal of Gynecological Cancer